Understanding how TET2 protein changes affect blood stem cells
Critical roles of RNA m5C-MBD6-H2AK119ub deubiquitylation axis in TET2-mediated HSC regulation
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · NIH-11087670
This research explores how changes in a protein called TET2 contribute to blood disorders and how we might correct them.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER (nih funded) |
| Locations | 1 site (SAN ANTONIO, UNITED STATES) |
| Trial ID | NIH-11087670 on ClinicalTrials.gov |
What this research studies
Many adults with blood cancers and other blood conditions have mutations in a protein called TET2, which plays a key role in how blood stem cells grow and develop. This project aims to understand a new way TET2 works by looking at how it modifies RNA, a molecule similar to DNA, within these stem cells. By uncovering how TET2's activity on RNA influences the health and behavior of blood stem cells, we hope to find new ways to address these blood disorders. This work could reveal important mechanisms that lead to the development of blood cancers.
Who could benefit from this research
Good fit: This foundational research is relevant to patients with adult myeloid malignancies or clonal hematopoiesis who have TET2 mutations.
Not a fit: Patients seeking immediate new treatments will not directly benefit from this basic science research, as it is focused on understanding disease mechanisms.
Why it matters
Potential benefit: If successful, this work could lead to new targets for developing treatments for adult myeloid malignancies and other blood conditions linked to TET2 mutations.
How similar studies have performed: This research builds upon recent discoveries in chromatin regulation and RNA modification, exploring a novel mechanism of TET2 function.
Where this research is happening
SAN ANTONIO, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCIENCE CENTER — SAN ANTONIO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: XU, MINGJIANG — UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
- Study coordinator: XU, MINGJIANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.